Glioblastoma multiforme therapy and mechanisms of resistance
Pharmaceuticals, ISSN: 1424-8247, Vol: 6, Issue: 12, Page: 1475-1506
2013
- 189Citations
- 148Usage
- 304Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations189
- Citation Indexes189
- 189
- CrossRef172
- Usage148
- Downloads132
- Abstract Views16
- Captures304
- Readers304
- 302
- Mentions1
- News Mentions1
- 1
Most Recent News
Why glioblastoma tumors like John McCain’s are so aggressive
Sen. John McCain, R-Ariz., has been diagnosed with a brain cancer known as a glioblastoma. The tumor was discovered when McCain’s doctors removed a blood clot from above his left eye, which speaks to how the disease may have formed in the first place. (More on that later.) Though it’s is rare overall, with 12,000 new cases expected this year, glioblastoma is the most lethal type of brain cancer. G
Review Description
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy. © 2013 by the authors; licensee MDPI, Basel, Switzerland.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84888325792&origin=inward; http://dx.doi.org/10.3390/ph6121475; http://www.ncbi.nlm.nih.gov/pubmed/24287492; https://www.mdpi.com/1424-8247/6/12/1475; https://escholarship.umassmed.edu/gsbs_sp/1869; https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2889&context=gsbs_sp; https://dx.doi.org/10.3390/ph6121475; https://www.mdpi.com/1424-8247/6/12/1475/pdf?version=1385484244; https://www.mdpi.com/1424-8247/6/12/1475/htm; http://www.mdpi.com/1424-8247/6/12/1475; https://www.mdpi.com/1424-8247/6/12/1475/pdf; http://www.mdpi.com/1424-8247/6/12/1475/
MDPI AG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know